UFP Technologies (UFPT) Q4 2025 earnings summary

Executive summary

• Achieved 19.5% sales growth for 2025, reaching $602.8 million in revenue, nearly tripling since 2021, with record net income of $68.3 million, up 15.8% year-over-year.

• Operating income grew 14.1% to $92.3 million, and EPS increased 15.4% to $8.75, despite $6.3 million in labor inefficiencies.

• Significant progress on strategic initiatives: contract extensions, program launches, facility expansions, and talent acquisition.

• CEO transition to Mitch Rock is on track for June, with outgoing CEO remaining as executive chair for one year.

• Integration of seven acquisitions over 2024–2025 is progressing well, supporting future growth.

Financial highlights

• Gross margin decreased to 28.3% in 2025 due to $6.3 million in extra labor costs; would have been 29.3% excluding these costs.

• Adjusted operating margin for the year was 17.1%, within the 17%-20% target range; adjusted EBITDA margin was 20.1%.

• Effective tax rate dropped to 17.2% due to increased pre-tax income in the Dominican Republic.

• Generated $92 million in cash from operations; $12.9 million in capital expenditures and three acquisitions funded.

• Paid down $53.9 million in debt, ending with a leverage ratio of 1.1x; long-term debt reduced to $122.96 million.

Outlook and guidance

• Expecting robust growth in patient services and safe patient handling markets in 2026, with expansion in the Dominican Republic and new program launches.

• Three new programs launched: one in infection prevention, two in robotic surgery, expected to drive future growth.

• Backlog from AJR labor issues will be worked down through 2026, with overtime and temporary labor transitioning to permanent.

• No specific volume guidance for largest customer due to confidentiality, but contract extension is a material increase.

• Robust pipeline and new contract extensions with major customers support a bullish outlook.